Higher magnetic susceptibility of globus pallidus in patients after macrocyclic GBCAs: assessment using quantitative susceptibility mapping

Abstract

Background

As previous studies reported, gadolinium deposits in globus pallidus (GP) and dentate nucleus (DN) after repeated administrations of gadolinium-based contrast agents (GBCAs) and a signal intensity (SI) increase on T1-weighted images were related to linear GBCAs, not macrocyclic GBCAs.

Purpose

To identify whether quantitative susceptibility mapping (QSM) could measure a subtle increase in magnetic susceptibility in DN and GP in patients after repeated administrations of gadoteric acid meglumine (Gd-DOTA).

Material and Methods

In this study, 50 patients with cerebral tumors who had received at least three injections of Gd-DOTA (GBCA group) and 50 individuals without a history of GBCA injections (non-GBCA group) were included. The image data for QSM and T1-weighted images were reviewed. Spearman rank correlation was used to estimate the associations between the values (magnetic susceptibility of QSM and SI ratios of T1-weighted images) and the number of Gd-DOTA injections.

Results

The mean magnetic susceptibility of GP in GBCA group was 0.136 ± 0.031 ppm, which was significantly higher than that in control group (0.114 ± 0.030 ppm) (P = 0.001). In the GBCA group (n = 50), we found a substantial positive correlation between magnetic susceptibility of GP and the number of Gd-DOTA injections according to Spearman rank correlation coefficient (ρ = 0.673, P = 0.0001). There was a modest but significant correlation between magnetic susceptibility of DN and the number of Gd-DOTA injections (ρ = 0.311, P = 0.028).

Conclusion

In comparison to the control group, the magnetic susceptibility of GP in the GBCA group was significantly higher and had a substantial positive association with the number of Gd-DOTA injections.

Keywords

Gd-DOTA magnetic susceptibility T1 ratios the number of Gd-DOTA injections quantitative susceptibility mapping

Get full access to this article

View all access options for this article.

References

Mathur

Jones

Weinreb

. Gadolinium deposition and nephrogenic systemic fibrosis: a radiologist’s primer. Radiographics 2020;40:153–162.

McDonald

. MR imaging safety considerations of gadolinium-based contrast agents: gadolinium retention and nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 2020;28:497–507.

Kiviniemi

Gardberg

, et al. Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents. Neuroradiology 2019;61:535–544.

Kobayashi

Levendovszky

Hippe

, et al. Comparison of human tissue gadolinium retention and elimination between gadoteridol and gadobenate. Radiology 2021;300:559–569.

Rowe

Rodriguez

Cohen

, et al. Switching from linear to macrocyclic gadolinium-based contrast agents halts the relative T1 -weighted signal increase in deep gray matter of children with brain tumors: a retrospective study. J Magn Reson Imaging 2020;51:288–295.

Jost

Frenzel

Boyken

, et al. Long-term excretion of gadolinium-based contrast agents: linear versus macrocyclic agents in an experimental rat model. Radiology 2019;290:340–348.

Yoo

Sohn

Kang

, et al. Evaluation of gadolinium retention after serial administrations of a macrocyclic gadolinium-based contrast agent (gadobutrol): a single-institution experience with 189 patients. Invest Radiol 2018;53:20–25.

Olchowy

Cebulski

Lasecki

, et al. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - a systematic review. PLoS One 2017;12:e0171704.

Berger

Kubik-Huch

Niemann

, et al. Gadolinium distribution in cerebrospinal fluid after administration of a gadolinium-based MR contrast agent in humans. Radiology 2018;288:703–709.

10.

Bussi

Coppo

Celeste

, et al. Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats. Insights Imaging 2020;11:11.

11.

Taoka

Naganawa

. Gadolinium-based contrast media, cerebrospinal fluid and the glymphatic system: possible mechanisms for the deposition of gadolinium in the brain. Magn Reson Med Sci 2018;17:111–119.

12.

Nehra

McDonald

Bluhm

, et al. Accumulation of gadolinium in human cerebrospinal fluid after gadobutrol-enhanced MR imaging: a prospective observational cohort study. Radiology 2018;288:416–423.

13.

Rasschaert

Weller

Schroeder

, et al. Retention of gadolinium in brain parenchyma: pathways for speciation, access, and distribution. A critical review. J Magn Reson Imaging 2020;52:1293–1305.

14.

Choi

Jang

Kim

, et al. MRI and quantitative magnetic susceptibility maps of the brain after serial administration of gadobutrol: a longitudinal follow-up study. Radiology 2020;297:143–150.

15.

Hinoda

Fushimi

Okada

, et al. Quantitative assessment of gadolinium deposition in dentate nucleus using quantitative susceptibility mapping. J Magn Reson Imaging 2017;45:1352–1358.

16.

Wang

Spincemaille

Liu

, et al. Clinical quantitative susceptibility mapping (QSM): biometal imaging and its emerging roles in patient care. J Magn Reson Imaging 2017;46:951–971.

17.

Wang

Prince

Quantitative susceptibility mapping is superior to t1-weighted imaging for detecting and measuring gadolinium. Radiology 2020;297:151–153.

18.

Quattrocchi

Ramalho

van der Molen

, et al. Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) task force position statement. Eur Radiol 2019;29:3959–3967.

19.

Yedavalli

DiGiacomo

Tong

, et al. High-resolution structural magnetic resonance imaging and quantitative susceptibility mapping. Magn Reson Imaging Clin N Am 2021;29:13–39.

20.

Zhang

, et al. Increased brain iron deposition in the putamen in patients with type 2 diabetes mellitus detected by quantitative susceptibility mapping. J Diabetes Res 2020;2020:7242530.

21.

Bollmann

Kristensen

Larsen

, et al. SHARQnet - sophisticated harmonic artifact reduction in quantitative susceptibility mapping using a deep convolutional neural network. Z Med Phys 2019;29:139–149.

22.

Karsa

Punwani

Shmueli

. An optimized and highly repeatable MRI acquisition and processing pipeline for quantitative susceptibility mapping in the head-and-neck region. Magn Reson Med 2020;84:3206–3222.

23.

Milovic

Bilgic

Zhao

, et al. Weak-harmonic regularization for quantitative susceptibility mapping. Magn Reson Med 2019;81:1399–1411.

24.

De Leon-Rodriguez

Martins

Pinho

, et al. Basic MR relaxation mechanisms and contrast agent design. J Magn Reson Imaging 2015;42:545–565.

25.

Colgan

Knobloch

Reeder

, et al. Sensitivity of quantitative relaxometry and susceptibility mapping to microscopic iron distribution. Magn Reson Med 2020;83:673–680.

26.

Langkammer

Schweser

Krebs

, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 2012;62:1593–1599.

27.

Saake

Schmidle

Kopp

, et al. MRI brain signal intensity and relaxation times in individuals with prior exposure to gadobutrol. Radiology 2019;290:659–668.

28.

Deike-Hofmann

Reuter

Haase

, et al. No changes in t1 relaxometry after a mean of 11 administrations of gadobutrol. Invest Radiol 2020;55:381–386.

29.

Popescu

Robinson

Rajput

, et al. Iron, copper, and zinc distribution of the cerebellum. Cerebellum 2009;8:74–79.

30.

Erikson

Syversen

Steinnes

, et al. Globus pallidus: a target brain region for divalent metal accumulation associated with dietary iron deficiency. J Nutr Biochem 2004;15:335–341.

31.

Feng

Xiao

, et al. Neurotoxicological consequence of long-term exposure to lanthanum. Toxicol Lett 2006;165:112–120.

32.

Zhang

Cao

Shih

, et al. Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology 2017;282:516–525.